Latest & greatest articles for doxycycline

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on doxycycline or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on doxycycline and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for doxycycline

1. One Dose of Doxycycline for the Prevention of Lyme Disease: A Review of Clinical Effectiveness and Guidelines

One Dose of Doxycycline for the Prevention of Lyme Disease: A Review of Clinical Effectiveness and Guidelines One Dose of Doxycycline for the Prevention of Lyme Disease: A Review of Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need One Dose of Doxycycline for the Prevention of Lyme Disease: A Review of Clinical Effectiveness and Guidelines One Dose of Doxycycline for the Prevention of Lyme Disease: A Review of Clinical Effectiveness and Guidelines Last updated: May (...) 21, 2019 Project Number: RC1121-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of one dose of doxycycline for the prevention of Lyme disease in patients with tick attachment? Are the evidence-based guidelines associated with the use of one dose of doxycycline for the prevention of Lyme disease in patients with tick attachment? Key Message Based primarily on a very-low quality randomized controlled

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

2. Doxycycline may be a safer first option for treating a blistering skin condition

Doxycycline may be a safer first option for treating a blistering skin condition Doxycycline may be a safer first option for treating a blistering skin condition Discover Portal Discover Portal Doxycycline may be a safer first option for treating a blistering skin condition Published on 4 July 2017 doi: Doxycycline (an established antibiotic) may be a safer first option than the standard steroid treatment for people with the autoimmune skin condition bullous pemphigoid. The condition causes (...) severe, itchy blistering. This NIHR-funded study showed that people started on doxycycline were 19% less likely to have severe, life-threatening or fatal events during the next 12 months than those who started a steroid (prednisolone). Blister control was considered acceptable for both treatments (74% treatment success with doxycycline at six weeks compared to 91% with a steroid). Whole-body steroid cream treatment might give better results, but is not always practical. Oral steroids are often used

2019 NIHR Dissemination Centre

3. Topical doxycycline for the management of recurrent aphthous ulcer: a systematic review

Topical doxycycline for the management of recurrent aphthous ulcer: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2019 PROSPERO

4. The efficacy of combination of doxycycline, rifampicin or streptomycin in the treatment of human Brucellosis: a review and meta analysis

The efficacy of combination of doxycycline, rifampicin or streptomycin in the treatment of human Brucellosis: a review and meta analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration

2019 PROSPERO

5. Doxycycline

Doxycycline Top results for doxycycline - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4 (...) ) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for doxycycline The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you

2018 Trip Latest and Greatest

6. Doxycycline may be a safer first option for treating a blistering skin condition

Doxycycline may be a safer first option for treating a blistering skin condition Doxycycline may be a safer first option for treating a blistering skin condition Discover Portal Discover Portal Doxycycline may be a safer first option for treating a blistering skin condition Published on 4 July 2017 doi: Doxycycline (an established antibiotic) may be a safer first option than the standard steroid treatment for people with the autoimmune skin condition bullous pemphigoid. The condition causes (...) severe, itchy blistering. This NIHR-funded study showed that people started on doxycycline were 19% less likely to have severe, life-threatening or fatal events during the next 12 months than those who started a steroid (prednisolone). Blister control was considered acceptable for both treatments (74% treatment success with doxycycline at six weeks compared to 91% with a steroid). Whole-body steroid cream treatment might give better results, but is not always practical. Oral steroids are often used

2018 NIHR Dissemination Centre

7. Effectiveness of systemic doxycycline as an adjunct to scaling and root planing in diabetic patients with periodontitis. A systematic review and meta-analysis

Effectiveness of systemic doxycycline as an adjunct to scaling and root planing in diabetic patients with periodontitis. A systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr

2018 PROSPERO

8. Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial. Full Text available with Trip Pro

Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial. Bullous pemphigoid is a blistering skin disorder with increased mortality. We tested whether a strategy of starting treatment with doxycycline gives acceptable short-term blister control while conferring long-term safety advantages over starting treatment with oral corticosteroids.We did a pragmatic, multicentre, parallel-group randomised controlled (...) trial of adults with bullous pemphigoid (three or more blisters at two or more sites and linear basement membrane IgG or C3). Participants were randomly assigned to doxycycline (200 mg per day) or prednisolone (0·5 mg/kg per day) using random permuted blocks of randomly varying size, and stratified by baseline severity (3-9, 10-30, and >30 blisters for mild, moderate, and severe disease, respectively). Localised adjuvant potent topical corticosteroids (<30 g per week) were permitted during weeks 1-3

2017 Lancet Controlled trial quality: predicted high

9. A randomised controlled trial to compare the safety, effectiveness and cost effectiveness of doxycycline (200 mg/day) with oral prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid: the Bullous Pemphigoid Steroids and Tetracyclines (BL

A randomised controlled trial to compare the safety, effectiveness and cost effectiveness of doxycycline (200 mg/day) with oral prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid: the Bullous Pemphigoid Steroids and Tetracyclines (BL A randomised controlled trial to compare the safety, effectiveness and cost effectiveness of doxycycline (200 mg/day) with oral prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid: the Bullous Pemphigoid Steroids

2017 NIHR HTA programme

10. Effect of locally delivered doxycycline as an adjunctive therapy to scaling and root planing in treatment of periodontitis in smokers: a systematic review and meta-analysis of randomized controlled trials

Effect of locally delivered doxycycline as an adjunctive therapy to scaling and root planing in treatment of periodontitis in smokers: a systematic review and meta-analysis of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files

2017 PROSPERO

11. Azithromycin versus Doxycycline for Chlamydia. (Abstract)

Azithromycin versus Doxycycline for Chlamydia. 27144856 2016 05 05 2018 12 02 1533-4406 374 18 2016 05 05 The New England journal of medicine N. Engl. J. Med. Azithromycin versus Doxycycline for Chlamydia. 1787 10.1056/NEJMc1600830 Geisler William M WM Perry Raymond C W RC Kerndt Peter R PR eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Anti-Bacterial Agents 83905-01-5 Azithromycin N12000U13O Doxycycline AIM IM N Engl J Med. 2015 Dec 24;373(26):2512-21 26699167 N Engl J Med (...) . 2016 May 5;374(18):1786 27144857 N Engl J Med. 2016 May 5;374(18):1786-7 27144858 Anti-Bacterial Agents therapeutic use Azithromycin therapeutic use Chlamydia Infections drug therapy Chlamydia trachomatis Doxycycline therapeutic use Female Humans Male 2016 5 5 6 0 2016 5 6 6 0 2016 5 6 6 1 ppublish 27144856 10.1056/NEJMc1600830 10.1056/NEJMc1600830#SA3

2016 NEJM

12. Azithromycin versus Doxycycline for Chlamydia. Full Text available with Trip Pro

Azithromycin versus Doxycycline for Chlamydia. 27144857 2016 05 05 2018 12 02 1533-4406 374 18 2016 05 05 The New England journal of medicine N. Engl. J. Med. Azithromycin versus Doxycycline for Chlamydia. 1786 10.1056/NEJMc1600830 Schachter Julius J University of California, San Francisco, San Francisco, CA julius.schachter@ucsf.edu. eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Anti-Bacterial Agents 83905-01-5 Azithromycin N12000U13O Doxycycline AIM IM N Engl J Med. 2015 (...) Dec 24;373(26):2512-21 26699167 N Engl J Med. 2016 May 5;374(18):1787 27144856 Anti-Bacterial Agents therapeutic use Azithromycin therapeutic use Chlamydia Infections drug therapy Chlamydia trachomatis Doxycycline therapeutic use Female Humans Male 2016 5 5 6 0 2016 5 6 6 0 2016 5 6 6 1 ppublish 27144857 10.1056/NEJMc1600830 10.1056/NEJMc1600830#SA1

2016 NEJM

13. Azithromycin versus Doxycycline for Chlamydia. Full Text available with Trip Pro

Azithromycin versus Doxycycline for Chlamydia. 27144858 2016 05 05 2018 12 02 1533-4406 374 18 2016 05 05 The New England journal of medicine N. Engl. J. Med. Azithromycin versus Doxycycline for Chlamydia. 1786-7 10.1056/NEJMc1600830 Kreuter Alexander A Helios St. Elisabeth Hospital, Oberhausen, Germany alexander.kreuter@helios-kliniken.de. Wieland Ulrike U University of Cologne, Cologne, Germany. eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Anti-Bacterial Agents 83905-01-5 (...) Azithromycin N12000U13O Doxycycline AIM IM N Engl J Med. 2015 Dec 24;373(26):2512-21 26699167 N Engl J Med. 2016 May 5;374(18):1787 27144856 Anti-Bacterial Agents therapeutic use Azithromycin therapeutic use Chlamydia Infections drug therapy Chlamydia trachomatis Doxycycline therapeutic use Female Humans Male 2016 5 5 6 0 2016 5 6 6 0 2016 5 6 6 1 ppublish 27144858 10.1056/NEJMc1600830 10.1056/NEJMc1600830#SA2

2016 NEJM

14. Doxycycline plus ivermectin versus ivermectin alone for treatment of patients with onchocerciasis. Full Text available with Trip Pro

Doxycycline plus ivermectin versus ivermectin alone for treatment of patients with onchocerciasis. Onchocerciasis, also known as "river blindness," is a parasitic disease that is caused by infection from the filarial nematode (roundworm), Onchocerca volvulus. Nematodes are transmitted from person to person by blackflies of the Simulium genus, which usually breed in fast flowing streams and rivers. The disease is the second leading infectious cause of blindness in endemic areas.Ivermectin (...) (a microfilaricide) is widely distributed to endemic populations for prevention and treatment of onchocerciasis. Doxycycline, an antibiotic, targets Wolbachia organisms that are crucial to the survival of adult onchocerca (macrofilaricide). Combined treatment with both drugs is believed to cause direct microfilarial death by ivermectin and indirect macrofilarial death by doxycycline. Long-term reduction in the numbers of microfilaria in the skin and eyes and in the numbers of adult worms in the body has

2016 Cochrane

15. Does doxycycline affect clinical outcomes or joint health in patients undergoing joint preservation surgery of the hip or knee? A systematic review

Does doxycycline affect clinical outcomes or joint health in patients undergoing joint preservation surgery of the hip or knee? A systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith

2016 PROSPERO

16. The efficacy of host response modulation using low dose of doxycycline or anti-inflammatory drugs on periodontal disease therapy: a systematic review

The efficacy of host response modulation using low dose of doxycycline or anti-inflammatory drugs on periodontal disease therapy: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith

2016 PROSPERO

17. Doxycycline plus ivermectin versus ivermectin alone for treating onchocerciasis [Cochrane Protocol]

Doxycycline plus ivermectin versus ivermectin alone for treating onchocerciasis [Cochrane Protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web

2015 PROSPERO

18. The efficacy of azithromycin and doxycycline for the treatment of rectal chlamydia infection: a systematic review and meta-analysis

The efficacy of azithromycin and doxycycline for the treatment of rectal chlamydia infection: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2014 PROSPERO

19. Doxycycline

Doxycycline USE OF DOXYCYCLINE IN PREGNANCY 0344 892 0909 USE OF DOXYCYCLINE IN PREGNANCY (Date of issue: June 2012 , Version: 2 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . Summary Doxycycline is a broad spectrum tetracycline antibiotic which is also used in the prophylaxis of malaria and as an adjunct to quinine (...) in the treatment of falciparum malaria. Exposure to doxycycline in early pregnancy has not been firmly associated with any specific malformations but its use in the second or third trimester can cause discolouration of the teeth. During pregnancy, travel to areas where malaria is endemic should be avoided wherever possible. If travel to such areas is unavoidable, chloroquine and proguanil are the preferred antimalarials to use during pregnancy. Doxycycline is best avoided for antimalarial prophylaxis during

2014 UK Teratology Information Service

20. Acticlate Tablets (Doxycycline hyclate)

Acticlate Tablets (Doxycycline hyclate) Drug Approval Package: Brand Omtryg capsules NDA 204977 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Acticlate Tablets (Doxycycline hyclate) Company: Aqua Pharmaceuticals Application No.: 205931 Approval Date: 7/25/2014 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

2014 FDA - Drug Approval Package